Glaxosmi. Pharma

Why is Glaxosmithkline Pharmaceuticals Ltd falling/rising?

As of 07-Aug, Glaxosmithkline Pharmaceuticals Ltd's stock is rising at 2,593.05, with a 0.52% increase today and a positive trend over the past month. However, concerns about long-term growth and high valuation persist, as the stock has shown negative performance over the past year despite recent gains.

As of 07-Aug, Glaxosmithkline Pharmaceuticals Ltd's stock price is rising, currently at 2,593.05, reflecting a change of 13.45 (0.52%) upward. The stock has outperformed its sector by 0.67% today and has shown consecutive gains over the last two days, with a total return of 1.3% during this period. Additionally, the stock's performance over the past month has been positive, with a 7.91% increase compared to a 0.41% rise in the Sensex.<BR><BR>Despite these positive short-term movements, there are underlying factors that could influence future performance. The company has demonstrated high management efficiency with a return on equity (ROE) of 45.70% and is net-debt free, which are strong indicators of financial health. However, the stock has experienced poor long-term growth, with net sales growing at an annual rate of only 3.44% and operating profit at 14.36% over the last five years. Recent quarterly results have also shown declines in profit before tax (PBT) and profit after tax (PAT) compared to previous quarters.<BR><BR>While the stock is currently rising, it is trading at a high valuation with a price-to-book value of 19.4, which may be considered expensive relative to its peers. The stock's performance over the past year has been negative, with a return of -3.21%, despite a profit increase of 11.2%. This context suggests that while the stock is experiencing a rise at present, there are significant concerns regarding its long-term growth potential and valuation that investors should consider.

Which are the latest news on Glaxosmi. Pharma?

Are Glaxosmithkline Pharmaceuticals Ltd latest results good or bad?

GlaxoSmithKline Pharmaceuticals Ltd's latest results show a year-on-year net profit increase of 15.69% and revenue growth of 16.55%, but sequential declines in profit and revenue, along with reduced operating margins, indicate operational challenges. Overall, the financial trend is considered 'FLAT,' suggesting a cautious outlook for investors.

GlaxoSmithKline Pharmaceuticals Ltd's latest results present a mixed picture. On one hand, the company reported a year-on-year net profit increase of 15.69%, reaching ₹237.18 crores, and a revenue growth of 16.55% year-on-year, which indicates some strength in its topline performance. However, there are significant concerns regarding profitability and operational challenges.<BR><BR>Sequentially, the net profit declined by 14.64% and revenue fell by 5.71% compared to the previous quarter. This decline raises questions about the sustainability of demand and suggests potential operational headwinds. Additionally, the operating margin contracted to 31.49%, down from 35.26% in the previous quarter, reflecting increased cost pressures.<BR><BR>Overall, while there are positive indicators in terms of year-on-year growth, the sequential declines and margin compression suggest that the company's recent performance is not entirely favorable. Analysts have classified the financial trend as 'FLAT,' indicating a cautious outlook moving forward. Investors may need to monitor how the company addresses these challenges in upcoming quarters.

Should I buy, sell or hold Glaxosmithkline Pharmaceuticals Ltd?

How big is Glaxosmi. Pharma?

As of 10th June, Glaxosmithkline Pharmaceuticals Ltd has a market capitalization of 37,205.00 Cr and reported net sales of 3,821.67 Cr and net profit of 1,035.98 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Glaxosmithkline Pharmaceuticals Ltd has a market capitalization of 37,205.00 Cr, classified as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 3,821.67 Cr, while the sum of Net Profit for the same period is 1,035.98 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 2,267.42 Cr and Total Assets totaling 4,190.02 Cr.

Who are in the management team of Glaxosmi. Pharma?

The management team of Glaxosmi. Pharma includes Renu S Karnad (Chairperson), Bhushan Akshikar (Managing Director), J. Chandy (Whole Time Director & CFO), and several independent directors, bringing diverse expertise to the company.

The management team of Glaxosmi. Pharma includes the following members:<BR><BR>1. **Renu S Karnad** - Chairperson<BR>2. **Bhushan Akshikar** - Managing Director<BR>3. **J. Chandy** - Whole Time Director & CFO<BR>4. **D Sundaram** - Independent Director<BR>5. **P V Bhide** - Independent Director<BR>6. **A N Roy** - Independent Director<BR>7. **Sunita Maheshwari** - Independent Director<BR>8. **Manu Anand** - Independent Director<BR>9. **A A Nadkarni** - Company Secretary & Compliance Officer<BR>10. **Subesh Williams** - Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

Who are the peers of the Glaxosmi. Pharma?

Glaxosmi. Pharma's peers include Abbott India, Anthem Bioscienc, Ipca Labs, Ajanta Pharma, Gland Pharma, J B Chemicals, Emcure Pharma, Wockhardt, and Acutaas Chemical. Acutaas Chemical leads in 1-year returns at 186.50%, while Glaxosmi. Pharma has the lowest at -36.01%.

Peers: The peers of Glaxosmi. Pharma are Abbott India, Anthem Bioscienc, Ipca Labs, Ajanta Pharma, Gland Pharma, J B Chemicals &, Emcure Pharma, Wockhardt, Acutaas Chemical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Abbott India, Ajanta Pharma, and Glaxosmi. Pharma, while Good management risk is found at Anthem Bioscienc, Ipca Labs, Gland Pharma, J B Chemicals &, Emcure Pharma, and Acutaas Chemical, and Average management risk is noted at Wockhardt. Growth is rated as Excellent for Anthem Bioscienc and Acutaas Chemical, Average for Abbott India and Wockhardt, and Below Average for Ipca Labs, Ajanta Pharma, Gland Pharma, Glaxosmi. Pharma, J B Chemicals &, and Emcure Pharma. Excellent capital structure is seen at Abbott India, Anthem Bioscienc, Ipca Labs, Ajanta Pharma, Gland Pharma, Glaxosmi. Pharma, J B Chemicals &, and Acutaas Chemical, while Good capital structure is noted at Emcure Pharma, and Below Average at Wockhardt.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Acutaas Chemical at 186.50%, while Glaxosmi. Pharma has the lowest at -36.01%. This indicates that Glaxosmi. Pharma's performance is significantly worse than its peers. Additionally, Wockhardt is the only peer with a negative six-month return at -17.61%.

What does Glaxosmi. Pharma do?

GlaxoSmithKline Pharmaceuticals Limited, a subsidiary of GSK Plc., operates in the Pharmaceuticals & Biotechnology sector, reporting net sales of 995 Cr and a net profit of 278 Cr for March 2026. It has a market cap of INR 37,205 Cr, a P/E ratio of 36.00, and a dividend yield of 2.60%.

Overview: <BR>GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., operating in the Pharmaceuticals & Biotechnology industry within the mid-cap market segment.<BR><BR>History: <BR>The company is incorporated as a subsidiary of GSK Plc. The latest quarterly results reported are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 995 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 278 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 37,205 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 36.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 2.60% <BR>Debt Equity: -1.21 <BR>Return on Equity: 45.02% <BR>Price to Book: 16.40<BR><BR>Contact Details: <BR>Address: GSK House, Dr Annie Besant Road Worli Mumbai Maharashtra : 400030 <BR>Tel: 91-022-24959595 <BR>Email: askus@gsk.com <BR>Website: http://www.gsk-india.com

Has Glaxosmithkline Pharmaceuticals Ltd declared dividend?

Yes, Glaxosmithkline Pharmaceuticals Ltd has declared a dividend of 570%, amounting to ₹12 per share, with an ex-date of November 7, 2024. While recent total returns have shown volatility, the company has demonstrated positive growth over the longer term, particularly in the 2 to 5-year periods.

Glaxosmithkline Pharmaceuticals Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 570%<BR>- Amount per share: 12 per share<BR>- Ex-date: Nov-07-2024<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 3 Months period, the price return was -5.94%, the dividend return was 2.20%, resulting in a total return of -3.74%.<BR><BR>In the 6 Months period, the price return was -1.54%, the dividend return was 2.30%, leading to a total return of 0.76%.<BR><BR>Over the 1 Year period, the price return was -15.05%, the dividend return was 2.05%, culminating in a total return of -13.0%.<BR><BR>In the 2 Years period, the price return was 22.8%, the dividend return was 4.28%, resulting in a total return of 27.08%.<BR><BR>For the 3 Years period, the price return was 90.57%, the dividend return was 10.19%, leading to a total return of 100.76%.<BR><BR>In the 4 Years period, the price return was 63.56%, the dividend return was 12.80%, culminating in a total return of 76.36%.<BR><BR>Over the 5 Years period, the price return was 62.24%, the dividend return was 15.06%, resulting in a total return of 77.3%.<BR><BR>Overall, Glaxosmithkline Pharmaceuticals Ltd has declared a significant dividend, and while the recent total returns show some volatility, the longer-term performance indicates positive growth, particularly over the 2 to 5-year periods.

How has been the historical performance of Glaxosmi. Pharma?

Glaxosmi. Pharma has shown consistent growth in net sales and profitability from March 2019 to March 2025, with net sales increasing from 3,128.12 crore to 3,749.21 crore and profit after tax rising from 445.39 crore to 927.58 crore. The company's operating profit margin improved significantly, reflecting enhanced operational efficiency.

Answer:<BR>The historical performance of Glaxosmi. Pharma shows a consistent growth trend in net sales and profitability over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Glaxosmi. Pharma's net sales have increased from 3,128.12 crore in March 2019 to 3,749.21 crore in March 2025, reflecting a steady upward trajectory. The total operating income followed a similar pattern, rising from 3,128.12 crore in March 2019 to 3,749.21 crore in March 2025. The company's operating profit (PBDIT) has also seen significant growth, climbing from 703.11 crore in March 2019 to 1,323.29 crore in March 2025, with an operating profit margin that improved from 19.21% to 31.4% over the same period. Profit before tax surged from 682.66 crore in March 2019 to 1,259.88 crore in March 2025, while profit after tax reached 927.58 crore in March 2025, up from 445.39 crore in March 2019. The earnings per share (EPS) increased notably from 26.29 in March 2019 to 54.75 in March 2025. On the balance sheet, total assets grew from 3,025.05 crore in March 2020 to 3,967.20 crore in March 2025, while total liabilities increased from 3,025.05 crore to 3,967.20 crore during the same period. The cash flow from operating activities improved significantly, reaching 1,289 crore in March 2025 compared to 490 crore in March 2020, indicating enhanced operational efficiency and cash generation capabilities.

Is Glaxosmi. Pharma technically bullish or bearish?

As of October 30, 2025, Glaxosmi Pharma's technical trend has shifted to a bearish stance, driven by bearish MACD, Bollinger Bands, moving averages, and KST indicators, despite a mildly bearish weekly outlook from Dow Theory.

As of 30 October 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and bearish moving averages on the daily chart. The KST is also bearish on the weekly, contributing to the overall bearish sentiment. Although the Dow Theory shows a mildly bearish weekly outlook and a bullish monthly perspective, the prevailing bearish indicators suggest a negative short-term trend for Glaxosmi. Pharma.

Who are the top shareholders of the Glaxosmi. Pharma?

The top shareholders of Glaxosmi. Pharma include Glaxo Group Limited with 35.99%, various promoters, mutual funds holding 5.17%, and 255 foreign institutional investors owning 4.52%. Individual investors account for 10.6% of the shares, indicating a significant concentration of ownership among promoters.

The top shareholders of Glaxosmi. Pharma include the following:<BR><BR>1. **Glaxo Group Limited** - This entity is the largest shareholder, holding 35.99% of the company's shares.<BR>2. **Promoters** - They collectively hold the majority of the shares, although specific percentages beyond Glaxo Group Limited are not detailed.<BR>3. **Mutual Funds** - A total of 36 mutual fund schemes hold 5.17% of the shares.<BR>4. **Foreign Institutional Investors (FIIs)** - 255 FIIs collectively own 4.52% of the company.<BR>5. **SBI Nifty Midcap 150 Index Fund** - This is the highest public shareholder, holding 1.27%.<BR>6. **Individual Investors** - They account for 10.6% of the shareholding.<BR><BR>This distribution highlights a significant concentration of ownership among the promoters, particularly Glaxo Group Limited.

Is Glaxosmi. Pharma overvalued or undervalued?

As of November 16, 2023, Glaxosmi. Pharma is considered very expensive and overvalued with a PE ratio of 62.68, significantly higher than its peers, despite a strong ROE of 47.36% and a year-to-date return of 53.11%.

As of 16 November 2023, Glaxosmi. Pharma's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 62.68, an EV to EBITDA ratio of 47.07, and a Price to Book Value of 29.69, all of which are substantially higher than industry norms.<BR><BR>In comparison to its peers, Glaxosmi. Pharma's PE ratio is notably higher than Sun Pharma's 35.25 and Cipla's 22.99, which are categorized as expensive and attractive, respectively. Additionally, the company's ROE stands at a remarkable 47.36%, yet this is overshadowed by its very high valuation metrics. Despite outperforming the Sensex with a year-to-date return of 53.11% compared to the Sensex's 5.63%, the elevated valuation ratios suggest that the stock may not be a prudent investment at this time.

When is the next results date for Glaxosmi. Pharma?

No Upcoming Board Meetings

What is the bonus history of the Glaxosmi. Pharma?

Glaxosmithkline Pharmaceuticals Ltd issued a 1:1 bonus share on September 11, 2018, with a record date of September 13, 2018, meaning shareholders received one additional share for each share held.

Glaxosmi. Pharma, officially known as Glaxosmithkline Pharmaceuticals Ltd, has a notable bonus history. The most recent bonus issue was a 1:1 bonus, which was announced with an ex-date of September 11, 2018. The record date for this bonus was September 13, 2018. This means that shareholders received one additional share for every share they held as of the record date. If you have any more questions about the company or its financials, feel free to ask!